Therapeutic use of monoclonal anti-idiotype antibodies against B-cell lymphoma
Human malignant B-cell tumors arise from a proliferation of a single clone of cells . The immunoglobulin (Ig) which is expressed by the tumor cells is limited to the expression of one single VH and VL region, and to a single light chain. The unique variable region of the Ig, the idiotype, thus forms a specific tumor marker and a potential target for immunotherapy. Levy and colleagues  used a monoclonal anti-idiotype antibody to treat a patient with a nodular poorly-differentiated lymphocytic lymphoma, and achieved a complete remission which has lasted so far for 29 months. This group has treated seven more patients with anti-idiotype antibodies but no complete remissions have been obtained . Polyclonal anti-idiotype antibodies raised in sheep have been given to one patient with promyelocytic leukemia  and to three patients with lymphoma . There were transient reductions in the level of circulating lymphocytes, but no long-lasting antitumor effect was seen.
KeywordsChronic Lymphocytic Leukaemia Hodgkin Lymphoma Circulate Tumor Cell Ascitic Fluid Netherlands Cancer Institute
Unable to display preview. Download preview PDF.
- 3.Lowder JN, Meeker TC, Maloney DG et al. (1984). Anti-idiotype monoclonal antibody therapy of human B-lymphocytic malignancy. Proc Amer Soc Clin Oncol 3: 250.Google Scholar
- 5.Macbeth FR, Stevenson FK, Stevenson GT and Whitehouse JMA (1983). Anti-idiotype antibody therapy of patients with non-Hodgkin’s lymphoma. Proceed 2nd Eur Conf Clin Oncol Cancer Nursing. Amsterdam, p. 75.Google Scholar
- 7.Mauer AM, Murphy SB, Hayes AB and Dahl GV (1977). Scheduling and recruitment in malignant cell populations. In: Drewinko B and Humphrey EM (Eds.). Growth Kinetics and Biochemical Regulation of Normal and Malignant Cells, pp. 855–864. Baltimore: Williams & Wilkins.Google Scholar
- 14.Zimmerman TS, Godwin HA and Perry S (1968). Studies of leukocyte kinetics in chronic lymphocytic leukaemia. Blood 51: 277–191.Google Scholar